Christensen Jakob Wedel Sells 1,033 Shares of Illumina (NASDAQ:ILMN) Stock
Illumina SVP Christensen Jakob Wedel sold 1,033 shares of the company's stock for approximately $197,840, reducing his direct ownership by 6.86% to 14,023 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite mixed analyst sentiment and a consensus "Hold" rating, Illumina's shares traded near their 52-week high, and the company surpassed its recent quarterly earnings and revenue expectations.
Illumina (NASDAQ: ILMN) SVP sells 1,033 shares in planned trade
Jakob Wedel Christensen, SVP, Strategy/Corp Development at Illumina (NASDAQ: ILMN), sold 1,033 shares of common stock on August 18, 2026, at a price of $191.52 per share. This transaction was conducted under a Rule 10b5-1 trading plan, and after the sale, Christensen directly holds 14,023 shares. The sale totaled approximately $198,000 and was reported in a Form 4 filing.
Illumina stock hits 52-week high at 207.1 USD
Illumina Inc. (ILMN) stock has reached a new 52-week high of $207.1 USD, reflecting a significant 108.22% increase over the past year. Despite its current trading price of $162.64 and a strong gross profit margin of 68%, InvestingPro's analysis suggests the stock remains undervalued. The company recently announced a $300 million note offering to refinance debt and has received various analyst rating changes and price target adjustments.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 8.87% to $205.00, outperforming the broader market. This occurred during a favorable trading session where the S&P 500 Index and Dow Jones Industrial Average also saw gains. The company's stock closed just shy of its 52-week high.
Illumina Stock Is Up 40% Since January. Should You Still Ride the Wave in 2026?
Illumina stock (ILMN) has rallied 40% since January, reaching a 52-week high of $204 before settling at $188, driven by strong Q2 results and raised guidance, particularly in its clinical sequencing business. Wall Street analysts are now playing catch-up, revising their price targets upward, although the TIKR model suggests a more measured annualized return of 7% by December 2030, valuing ILMN at $254. The core of the investment thesis remains the sustained growth in clinical sequencing, supported by the NovaSeq X and increasing consumables revenue.
Weekly Recap: Icahn Partners settlement and MiSeq i100 reagent rental
Illumina, Inc. (ILMN) recently settled litigation with Icahn Partners, with the mutual release effective August 21, 2025. Additionally, Illumina expanded its Next-Generation Sequencing (NGS) access in Italy by implementing a multi-year reagent-rental agreement for a MiSeq i100 with Devyser, which shifts capital expenditure to predictable reagent spending. This move aims to enhance NGS accessibility in the region.
Assenagon Asset Management S.A. Grows Holdings in Illumina, Inc. $ILMN
Assenagon Asset Management S.A. significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 188.6% in the second quarter, now holding 140,003 shares valued at approximately $24.6 million. This comes as Illumina exceeded quarterly earnings and revenue expectations and maintained its fiscal 2026 EPS guidance. Despite strong institutional ownership and positive earnings, analyst sentiment remains mixed with a "Hold" consensus, and recent insider selling activity has been notable.
ETFs Investing in Illumina, Inc. Stocks
This article lists various ETFs that hold Illumina, Inc. (ILU) stocks, providing detailed financial information for each fund. The data includes market value, weight of ILU in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The aim is to help investors find opportunities with lower risk through diversified ETF investments.
ETFs Investing in Illumina, Inc. Stocks
This article lists various ETFs that invest in Illumina, Inc. (ILU) stocks, providing key financial data for each fund such as market value, weight of ILU in the ETF, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify ETFs holding Illumina, Inc. to potentially diversify their investments with lower risk.
Independent Director Keith Meister Sold A Bunch Of Shares In Illumina
Independent Director Keith Meister recently sold US$148m worth of Illumina (NASDAQ:ILMN) stock at US$200 per share, reducing his holding by 26%. While this is the largest insider sale in the last year, it occurred at approximately the current share price, mitigating some of the negative implications of insider selling. Despite recent sales, insiders still own 2.1% of the company, valued at US$609m.
Empowered Funds LLC Increases Stock Holdings in Illumina, Inc. $ILMN
Empowered Funds LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 104.2% in the first quarter, now holding 12,996 shares valued at approximately $1.6 million. This comes as institutional investors collectively own 89.42% of the company, and Illumina reported strong Q1 earnings, beating estimates with $1.31 EPS and $1.16 billion in revenue. Despite mixed analyst opinions and recent insider selling totaling $303.9 million, the company maintained its fiscal 2026 EPS guidance of $5.30 to $5.40.
Equity awards tie Illumina, Inc. (ILMN) CCO pay to EPS and TSR
Illumina, Inc. (ILMN) granted its Chief Commercial Officer, Michael C. Sullivan, equity awards on August 5, 2026. These awards include restricted stock units and performance stock units, linking a portion of his compensation directly to the company's financial performance, specifically non-GAAP EPS growth and relative total shareholder return (TSR). The performance units have a payout range of 0% to 250% of the target, vesting on December 31, 2028, and are contingent on continued service.
Price to earnings forward of Illumina, Inc. – DUS:ILU
This page provides financial information for Illumina, Inc. (DUS:ILU) on the TradingView platform, specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades recorded for the company.
Illumina Inc (ILMN) News, Articles, Events & Latest Updates
This article compiles recent news and updates for Illumina Inc (ILMN), highlighting its stock performance and analyst ratings. Recent reports show Illumina was upgraded to a Zacks Rank #1 (Strong Buy), outperformed the market over 20 years, and reported strong Q2 2026 earnings and revenue. The company's financial results for Q2 2026 were also officially released on July 30, 2026.
Illumina Inc. stock underperforms Friday when compared to competitors
Illumina Inc. (ILMN) saw its stock slip 2.97% on Friday, closing at $187.96, underperforming the broader market. This marked the third consecutive day of losses for the company, even as the S&P 500 Index and Dow Jones Industrial Average both posted gains.
Illumina (ILMN) sees Corvex-advised funds sell 741,127 common shares
Illumina director Keith A. Meister reported that private investment funds advised by Corvex Management LP sold 741,127 shares of Illumina common stock between August 4-5, 2026. The sales occurred in multiple transactions at weighted-average prices ranging from $196.74 to $203.28 per share. This transaction significantly reduced the indirect holdings of Corvex-advised funds, though Meister maintains a direct holding of 6,780 shares.
Illumina Inc. stock underperforms Thursday when compared to competitors
Illumina Inc. (ILMN) stock dropped 3.08% on Thursday, closing at $193.72, underperforming the broader market. This marks the second consecutive day of losses for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw declines.
Illumina Inc. stock underperforms Wednesday when compared to competitors
Illumina Inc. (ILMN) stock declined 1.55% on Wednesday, closing at $199.87. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the S&P 500 Index falling. The stock is currently 3.44% below its 52-week high achieved on August 3rd.
Illumina, Inc. (ILMN) legal chief sells 615 shares in planned trade
Illumina's Chief Legal Officer, Scott M. Davies, sold 615 shares of common stock on July 30, 2026, at a price of $200.00 per share. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 20,338 shares directly owned. The sale, valued at $123,000, was an open market or private transaction.
Illumina Inc. stock underperforms Monday when compared to competitors
Illumina Inc. (ILMN) stock declined by 3.38% on Monday, closing at $198.16, despite an overall strong performance by the stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, making Illumina's drop noteworthy and ending a four-day winning streak for the company's shares.
Illumina’s CEO Says the Clinical Growth Isn’t a Cliff. Q2 Earnings Back Him Up.
Illumina reported strong Q2 2026 earnings, exceeding revenue and EPS estimates, driven primarily by robust clinical market growth. The company raised its full-year guidance for revenue and EPS, emphasizing the sustained demand for clinical sequencing, particularly with the NovaSeq X platform. TIKR's valuation model suggests a potential 22% total return for Illumina stock by 2030, reflecting confidence in the structural growth drivers rather than one-time gains.
ILLUMINA INC : PIPER SANDLER RAISES TARGET PRICE TO $225 FROM $200
Piper Sandler has increased its target price for Illumina Inc. (ILMN.O) to $225, up from the previous target of $200. This adjustment reflects the analyst's updated outlook on the company. The article notes that the content reflects the author's opinion and is not investment advice.
Illumina, Inc. Stock 12‑Month Price Target Raised to $193.61, Implies 6% Downside
Illumina, Inc.'s average stock price target has been raised from $175.72 to $193.61 by 18 analysts, with forecasts ranging from $95 to $230. This updated target implies a 6% potential downside based on the July 30 closing price. The consensus rating for the stock remains a "Buy" among 23 analysts.
Illumina, Inc. Stock 12‑Month Price Target Raised to $193.61, Implies 6% Downside
Illumina, Inc.'s average 12-month price target has been increased to $193.61 from $175.72 by 18 analysts, with forecasts ranging from $95 to $230 per share. This new target suggests a 6% potential downside based on the July 30 closing price. The consensus rating for ILMN remains "Buy" from 23 covering analysts.
ILLUMINA INC : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $140 FROM $120
BofA Global Research has increased its price objective for Illumina Inc. (ILMN.O) shares. The new target price is set at $140, up from the previous $120. This adjustment indicates a more positive outlook from the research firm regarding Illumina's future stock performance.
Illumina Looks Likely To Benefit From AI Initiatives in Life Sciences
Illumina is expected to gain from the growing integration of AI in life sciences, as highlighted by strong instrument sales and increasing AI opportunities boosting its 2026 outlook. The company's strategy involves leading genomic sequencing through innovation and acquisitions, addressing broad applications from population genomics to noninvasive prenatal screening. This continued focus positions Illumina to capitalize on the rapidly expanding uses of genomic sequencing tools.
Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations
Illumina (NASDAQ:ILMN) reported strong Q2 CY2026 results, with revenue of $1.16 billion exceeding analyst expectations and sales up 9.4% year-on-year. The company also raised its full-year revenue guidance to $4.62 billion and adjusted EPS guidance to $5.35 at the midpoint, both slightly above analyst estimates. Despite a history of tepid sales growth, this quarter's performance and revised outlook indicate positive momentum for the genomics company.
Illumina (ILMN) Stock Rises on Q2 2026 Earnings
Illumina (ILMN) reported strong Q2 2026 earnings with revenue up 9.4% to $1.16 billion, exceeding analyst expectations. Gross profit increased to $770 million, and diluted earnings per share were $1.35 against an expectation of $1.25, leading to a 3.86% rise in the company's stock after the market close. The article also details insider trading activity, hedge fund movements, government contracts, congressional stock trading, and analyst price targets for ILMN.
Earnings Flash (ILMN) Illumina, Inc. Posts Q2 Adjusted EPS $1.31 per Share, vs. FactSet Est of $1.23
Illumina, Inc. (ILMN) announced its Q2 adjusted EPS of $1.31 per share, surpassing FactSet’s estimate of $1.23. The company also reported Q2 revenue of $1.16 billion, exceeding FactSet's estimate of $1.13 billion, and provided earnings guidance for fiscal year 2026. The news highlighted the company's strong financial performance in the second quarter.
Earnings Flash (ILMN) Illumina, Inc. Reports Q2 Revenue $1.16B, vs. FactSet Est of $1.13B
Illumina, Inc. (ILMN) reported its second-quarter revenue at $1.16 billion, surpassing FactSet's estimate of $1.13 billion. The company specializes in DNA sequencing and array-based technologies for research, clinical, and applied markets, with products used in life sciences, oncology, reproductive health, and agriculture. Illumina also provided earnings guidance for fiscal year 2026, indicating positive financial performance.
Illumina, Inc. (Nasdaq: ILMN) lifts 2026 outlook after Q2 revenue hits $1.16B
Illumina, Inc. (Nasdaq: ILMN) reported strong Q2 2026 financial results with revenue reaching $1.16 billion, a 9.5% increase from the previous year. This performance led the company to raise its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. Key drivers included continued demand for NovaSeq X and expanding clinical customer applications, reinforcing confidence in the company's growth trajectory.
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Illumina, Inc. announced strong financial results for the second quarter of fiscal year 2026, with revenue reaching $1.16 billion, a 9.5% increase from Q2 2025. The company raised its fiscal year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40, driven by continued demand for its NovaSeq X technology and expansion in sequencing applications.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 5.27% to $205.09 on Thursday, contributing to its third consecutive day of gains. This performance outpaced the broader market, which also experienced a strong trading day with the S&P 500 Index rising 1.66% and the Dow Jones Industrial Average increasing by 1.19%.
Illumina, Inc. Revenue Breakdown – NASDAQ:ILMN
This article provides a revenue breakdown for Illumina, Inc. (NASDAQ: ILMN), highlighting that its top-performing segment is Core Illumina - Consumables, which generated $3.23 billion USD last year. The United States was the largest contributor to revenue, accounting for $2.24 billion USD in the latest year.
ILLUMINA, INC. (ILMN) names Chief Commercial Officer as insider with no holdings
Illumina, Inc. (ILMN) identified Michael C. Sullivan, its Chief Commercial Officer, as a reporting person for insider ownership purposes. This Form 3 filing indicates that Sullivan currently holds no reportable equity, derivative positions, or insider transactions with the company. The disclosure establishes his insider status without any listed beneficial ownership of securities.
Illumina Inc (ILMN) Valuation: PE, PB & Fair Value Analysis
Illumina Inc (ILMN) currently holds a valuation score of 9.61, positioning it 8th out of 199 companies in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 34.86, which is slightly below its recent high but significantly above its recent low. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Illumina Inc (ILMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Illumina Inc (ILMN), detailing its current price momentum score of 3.44 and suggesting it's suitable for range-bound swing trading between resistance at $203.15 and support at $178.79. It evaluates various technical indicators like MACD, RSI, and moving averages, with a summary indicating a neutral signal based on these metrics while showing multiple buy signals from moving averages. The analysis also includes FAQs explaining technical ratings and moving averages.
Illumina, Inc. Revenue Breakdown – LSX:927079
This article provides a revenue breakdown for Illumina, Inc. (LSX:927079), detailing its performance in the last fiscal year. The company generated 3.70 billion EUR, with its Core Illumina - Consumables segment being the top contributor at 2.75 billion EUR. Geographically, the United States was the largest market, accounting for 1.91 billion EUR.
At Michigan Medicine, WGS becomes the backbone of molecular pathology
Michigan Medicine has successfully integrated whole-genome sequencing (WGS) into its molecular pathology operations, moving away from fragmented, labor-intensive targeted panels. This strategic shift, led by Dr. Annette S. Kim, has resulted in faster turnaround times, reduced operational complexity, and expanded diagnostic capabilities. By partnering with the Michigan Genomics Initiative and investing in automation and informatics, the lab has significantly improved efficiency, data stewardship, and staff satisfaction while future-proofing its genomic research and clinical services.
Illumina CIO: In the AI Era, ‘Tech Leaders Are in the Driver’s Seat’
Illumina CIO Mark Field asserts that technology leaders are currently making critical decisions as AI transforms industries, positioning them in the "driver's seat." He emphasizes the importance of reimagining IT organizations around AI, fostering AI fluency within teams, and transitioning IT from an order-taker to a strategic business partner. Field believes that companies investing in their tech leaders will emerge stronger in this new AI-driven world, with CIOs potentially operating large "digital workforces."
Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger
Standard BioTools Inc. has announced strategic transactions aimed at streamlining its business and bolstering its balance sheet before its planned merger with Treeline Biosciences. The company sold its Mass Cytometry business to Multiplex Bio for up to $10 million, secured a $30 million buyout from Illumina for its former SomaLogic business, and received early antitrust clearance for the Treeline merger. These moves are intended to simplify operations, increase cash reserves for the merger, and position the combined entity with a stronger financial foundation and a more focused portfolio of life science research tools.
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Standard BioTools (NASDAQ: LAB) has announced key updates to advance its merger with Treeline Biosciences. The company is selling its Mass Cytometry business to Multiplex Bio for up to $10 million, ensuring continuity of its CyTOF and Hyperion product lines. Additionally, Standard BioTools received approximately $30 million from Illumina for the buyout of 2026 earnout and future royalty payments related to the previously acquired SomaLogic business.
Illumina Inc. stock underperforms Monday when compared to competitors
Illumina Inc. stock dropped 2.38% on Monday, closing at $189.47, despite a generally positive day for the broader stock market. The S&P 500 Index saw a slight increase of 0.02%, and the Dow Jones Industrial Average rose by 0.51%. This marked the second consecutive day of losses for Illumina.
(ILMN) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Illumina Inc. (NASDAQ: ILMN), focusing on institutional trading tactics and AI-generated signals. It highlights strong near-term sentiment, potential resistance testing, and an exceptional short-sell opportunity with a significant risk-reward ratio. The report also outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles.
Illumina Inc (ILMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Illumina Inc (ILMN) by business segments and geographic regions. As of April 6, 2026, Consumables represent the largest segment at 74.30% of revenue, while the United States accounts for over half of the company's regional revenue. The data is presented in a columnar format detailing revenue and proportion for each category.
Illumina stock trades steady as investors weigh restructuring and recovery prospects
Illumina's stock performance reflects ongoing restructuring efforts and the demand for core sequencing products. Investors are closely watching the company's recent divestments, margin improvements, and balance sheet strength to assess its potential for recovery in the genomics equipment market. Key drivers for future growth include sustained demand for genomic data, expansion into clinical diagnostics, and the success of new platform launches.
Illumina, Inc. Revenue Breakdown – BIVA:ILMN
This article provides a revenue breakdown for Illumina, Inc. (BIVA:ILMN), detailing its top-performing segment and geographical contributions. Last year, the company generated 78.29 billion MXN, with the Core Illumina - Consumables segment contributing the most at 58.18 billion MXN. The United States was the largest regional contributor, accounting for 40.44 billion MXN.
Illumina, Inc. Revenue Breakdown – BOATS:ILMN
This article provides a revenue breakdown for Illumina, Inc. (ILMN), detailing its performance by segment and geographic region. Last year, the company generated $4.34 billion, with the "Core Illumina - Consumables" segment contributing the most at $3.23 billion. The United States was the largest contributor by country, accounting for $2.24 billion.
Illumina Inc. stock underperforms Friday when compared to competitors
Illumina Inc. (ILMN) shares fell 1.41% on Friday, closing at $194.09, despite a positive day for the broader stock market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The company's stock is now 2.54% below its 52-week high reached on July 23rd.
ILMN6231083 Bond Profile — Key Metrics
This article provides key metrics for the Illumina, Inc. (ILMN) bond, ISIN ILMN6231083. It details the bond's issue date, maturity date, outstanding amount, face value, and coupon rate, alongside a brief description of Illumina, Inc. The bond has a 4.75% coupon and matures on December 12, 2030, with an outstanding amount of $500 million USD.
